EvolusEOLS
EOLS logo
Fair Value
US$20
Share price17 Jan
US$6.9465.3% undervalued intrinsic discount
Loading
1Y-25.05%
7D0%

Rewards Scale And Medical Education Will Drive Aesthetics Portfolio Higher Over The Long Term

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published
17 Jan 26
Views
26
Not Invested

Fair Value vs Share Price

US$20
vs US$6.9465.3% undervalued intrinsic discount
PastFuture-137m553m2015201820212024202620272029Revenue US$553.4mEarnings US$144.8m
24.6%
Revenue growth
26.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Evolus

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with reasonable growth potential.

Market capUS$460.3m
PB-15.9x
Estimated Growth14.4%
Dividend YieldN/A
Full analysis

CEO & management

David Moatazedi
CEO
6.2yrs
CEO Tenure

A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.